Edward J. Dulac III
EVP, Chief Financial Officer · Intellia Therapeutics, Inc.
- 2025
- Jul 24, 2026
- 5
Other insiders active in the same stocks
Insiders who reported open-market trades in the last 12 months at the companies Edward J. Dulac III files at. Multiple unrelated insiders buying the same stock within a short window, cluster buying, has historically been one of the strongest Form 4 signals.
- John M. Leonard - $1.44M in NTLA purchases and sales in the last 12 months
- Fred E. Cohen - $1.40M in NTLA purchases and sales in the last 12 months
- James Basta - $112K in NTLA purchases and sales in the last 12 months
- David Lebwohl - $110K in NTLA purchases and sales in the last 12 months
- Eliana Clark - $96K in NTLA purchases and sales in the last 12 months
- Michael P. Dube - $95K in NTLA purchases and sales in the last 12 months
More insiders (A-Z)
Browse nearby insider profiles in alphabetical order.
Frequently asked questions
Who is Edward J. Dulac III?
Edward J. Dulac III is a corporate insider, tracked as EVP, Chief Financial Officer of Intellia Therapeutics, Inc. (NTLA). InsiderAlpha holds 5 primary Form 4 filings for them, the earliest from 2025, updated as new SEC EDGAR filings are processed.
How many SEC Form 4 filings has Edward J. Dulac III submitted recently?
1 primary Form 4 filing in the last 90 days, covering 1 company.
Has Edward J. Dulac III been buying or selling stock?
Recorded transactions: 0 open-market purchases and 4 open-market sales ($339K) across all tracked filings.
